Illumina Tells PTAB To Invalidate Columbia Univ. DNA Patent
A biotech company told the U.S. Patent Trial and Appeal Board during oral arguments Tuesday that a Columbia University DNA sequencing patent should be ruled invalid due to obviousness and because...To view the full article, register now.
Already a subscriber? Click here to view full article